DABRAFENIB PLUS TRAMETINIB IS ACTIVE IN BRAFV600E ANAPLASTIC THYROID CANCER

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2018年 / 8卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [1] Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma
    Hamidi, Sarah
    Iyer, Priyanka C.
    Dadu, Ramona
    Gule-Monroe, Maria K.
    Maniakas, Anastasios
    Zafereo, Mark E.
    Wang, Jennifer R.
    Busaidy, Naifa L.
    Cabanillas, Maria E.
    THYROID, 2024, 34 (03) : 336 - 346
  • [2] Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma
    Wang, Jennifer R.
    Zafereo, Mark E.
    Dadu, Ramona
    Ferrarotto, Renata
    Busaidy, Naifa L.
    Lu, Charles
    Ahmed, Salmaan
    Gule-Monroe, Maria K.
    Williams, Michelle D.
    Sturgis, Erich M.
    Goepfert, Ryan P.
    Gross, Neil D.
    Lait, Stephen Y.
    Gunn, Gary Brandon
    Phan, Jack
    Rosenthal, David, I
    Fuller, Clifton David
    Morrison, William H.
    Iyer, Priyanka
    Cabanillas, Maria E.
    THYROID, 2019, 29 (08) : 1036 - 1043
  • [3] Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports
    White, Paul S.
    Pudusseri, Anita
    Lee, Stephanie L.
    Eton, Omar
    THYROID, 2017, 27 (09) : 1201 - 1205
  • [4] Dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer
    Jeon, Y-K.
    Jung, H. A.
    Park, S.
    Lee, S-H.
    Kim, T. H.
    Kim, S. W.
    Chung, J. H.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1299 - S1299
  • [5] Repeat Redifferentiation of Radioiodine Refractory BRAFV600E Mutated Thyroid Cancer with Dabrafenib
    Bogsrud, Trond
    Jacobsen, Marita
    Durski, Jolanta
    Larsen, Eivind
    Engelsen, Ola
    Haskjold, Olav Inge
    Castillejo, Miguel
    Bach-Gansmo, Tore
    Van Nostrand, Douglas
    THYROID, 2023, 33 (06) : 771 - 773
  • [6] Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer
    Subbiah, Vivek
    Lassen, Ulrik
    Gasal, Eduard
    Burgess, Paul
    Wainberg, Zev A.
    LANCET ONCOLOGY, 2020, 21 (11): : E516 - E516
  • [7] Detection of BRAFV600E by digital PCR on fine-needle aspirate enables rapid initiation of dabrafenib and trametinib in unresectable anaplastic thyroid carcinoma
    Buffet, Camille
    Allard, Lucie
    Guillerm, Erell
    Ghander, Cecile
    Mathy, Elise
    Lussey-Lepoutre, Charlotte
    Julien, Nicolas
    Touma, Eliane
    Quilhot, Pauline
    Godiris-Petit, Gaelle
    Lacorte, Jean-Marc
    Leenhardt, Laurence
    Denis, Jerome Alexandre
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 187 (03) : K33 - K38
  • [8] BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy With or Without Trametinib
    McClenahan, Phil
    Lin, Lynlee L.
    Tan, Jean-Marie
    Flewell-Smith, Ross
    Schaider, Helmut
    Jagirdar, Kasturee
    Atkinson, Victoria
    Lambie, Duncan
    Prow, Tarl W.
    Sturm, Richard A.
    Soyer, H. Peter
    JAMA DERMATOLOGY, 2014, 150 (10) : 1079 - 1082
  • [9] BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation
    Wang, Xumeng
    Ying, Tianxing
    Yuan, Jimeng
    Wang, Yue
    Su, Xingyun
    Chen, Shitu
    Zhao, Yurong
    Zhao, Yuanyuan
    Sheng, Jinghao
    Teng, Lisong
    Luo, Chi
    Wang, Weibin
    ENDOCRINE-RELATED CANCER, 2023, 30 (08)
  • [10] Dabrafenib in BRAFV600E mutant pilocytic astrocytoma
    Yasri, Sora
    Wiwanitkit, Viroj
    CHILDS NERVOUS SYSTEM, 2020, 36 (05) : 893 - 893
12345